Key highlights
- Confirmed systemic objective response rate of 84% by investigator assessment and 80% by BICR
- Deep molecular response achieved with 100% of patients reaching 90% ctDNA reduction by Cycle 3
- Clinical data confirms efficacy across PACC mutations and L861Q variants with no new CNS lesions
- Global Phase 3 registrational trial for enozertinib scheduled to begin in the first half of 2027
- Safety profile showed predominantly Grade 1 or 2 events with no treatment discontinuations due to toxicities
Clinical Data Presentation
During the ESMO Congress 2026, ORIC Pharmaceuticals presented updated results from its Phase 1b trial of enozertinib, an oral EGFR inhibitor. The study focused on patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR atypical and exon 20 insertion mutations. Of the 26 patients treated with an 80 mg daily dose, the investigator-assessed confirmed systemic objective response rate reached 84%. Notably, 65% of the enrolled population had brain metastases at baseline, a rate significantly higher than observed in competitor datasets. The drug demonstrated meaningful intracranial activity and was well-tolerated, with most treatment-related adverse events resolving through dose modifications rather than permanent discontinuations.
Pipeline and Strategic Progress
- Initiation of a global Phase 3 registrational trial for enozertinib is planned for the first half of 2027
- Full ctDNA clearance was achieved by 82% of patients, a metric associated with improved long-term survival in prior lung cancer trials
- Recent clinical development agreement with Cancer Research UK to advance ORIC-259 into Phase 1/2 trials as of October 2026
- Ongoing Himalayas-1 Phase 3 study for rinzimetostat bolstered by a supply collaboration with Bayer
- Development strategy remains focused on addressing diverse PACC and L861Q mutations that lack standard-of-care treatments
Business and Industry Landscape
ORIC Pharmaceuticals operates as a clinical-stage biotechnology company centered on overcoming resistance mechanisms in cancer therapy. The firm competes in a specialized oncology segment targeting specific epidermal growth factor receptor mutations. Its clinical pipeline, including enozertinib and rinzimetostat, aims to provide high-potency alternatives to existing inhibitors while maintaining blood-brain barrier penetration. Industry trends show a shift toward precision medicine where molecular response clearance, such as the 100% MR90 rate achieved in this trial, serves as a critical early indicator of long-term efficacy. The company’s focus on PACC mutations positions it to address a distinct subset of the non-small cell lung cancer market.
Financial Context
The company maintains a solid liquidity position to fund its transition into late-stage clinical development. According to financial updates from August 2026, ORIC holds approximately $387.6 million in cash and investments, which is projected to sustain operations into the second half of 2028. This runway follows a $125 million private placement financing completed in mid-2025. While the company does not currently generate revenue from commercial product sales, its market capitalization of $1.41 billion reflects significant investor interest in its pipeline milestones. The stock has demonstrated a 25.85% price increase over the last quarter, reflecting positive sentiment ahead of these registrational trial plans.
Down 44.8% since our story on 23 Oct: $13.63 when we broke it → $7.52 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $12.72 |
|---|---|
| 20 Oct | $13.78 |
| 21 Oct | $13.85 |
| 22 Oct | $13.63 |
| 23 Oct | $13.17 |
| 26 Oct | $8.96 |
| 27 Oct | $9.00 |
| 28 Oct | $9.30 |
| 29 Oct | $8.99 |
| 30 Oct | $9.24 |
| 2 Nov | $9.07 |
| 3 Nov | $9.59 |
| 4 Nov | $9.34 |
| 5 Nov | $8.49 |
| 6 Nov | $8.82 |
| 9 Nov | $9.23 |
| 10 Nov | $8.91 |
| 11 Nov | $9.00 |
| 12 Nov | $8.50 |
| 13 Nov | $7.86 |
| 16 Nov | $7.52 |
| Date | Announcement | Amount |
|---|---|---|
| 05 Oct 2026 | Clinical development agreement with Cancer Research UK to advance ORIC-259 into Phase 1/2 trialsSource: biospace.com | – |
| 03 Aug 2026 | Second quarter 2026 financial results and operational updatesSource: investors.oricpharma.com | – |
| 14 Jul 2026 | Initiation of Himalayas-1 Phase 3 trial and darolutamide supply collaboration with BayerSource: investors.oricpharma.com | – |
| 31 Mar 2026 | Selection of rinzimetostat recommended Phase 3 dose for Himalayas-1 studySource: investors.oricpharma.com | – |
| 12 Aug 2025 | Strategic pipeline reprioritization and 20% workforce reductionSource: investors.oricpharma.com | – |
| 28 May 2025 | Agreement for private placement financing of common stock and pre-funded warrantsSource: investors.oricpharma.com | $125.0 Million |
| Share price | $13.63 |
|---|---|
| Market cap | $1.4B |
| 1-month price change | +0.96% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by ORIC Pharmaceuticals, Inc. announcing updated Phase 1b clinical data for enozertinib at the ESMO Congress 2026.
Track Oric Pharmaceuticals, Inc. live
Get the next Oric Pharmaceuticals, Inc. SEC filing seconds after it lands.